All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 29, 2023
Home » Topics » Regulatory

Regulatory
Regulatory RSS Feed RSS

Product box for Everlywell's COVID-19 collection kit

FDA authorizes home sample kit for Everlywell, shuts down similar effort in Seattle

May 18, 2020
By Mark McCarty
No Comments
The FDA has granted an emergency use authorization (EUA) for the home sample collection kit made by Austin, Texas-based Everlywell Inc., which can be run on two lab-developed tests. However, the agency has also shut down a Gates Foundation-backed effort in Seattle to develop another home sample collection kit even though the organization behind the effort has been authorized by state health authorities. The FDA announced the news about the Everlywell EUA with the stipulation that the user of the kit has completed an online questionnaire that is subsequently reviewed by a health care professional.
Read More

Regulatory front for May 18, 2020

May 18, 2020
No Comments
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Applied Biosciences.
Read More

Regulatory actions for May 18, 2020

May 18, 2020
No Comments
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: 1drop, Agilent, Edwards, Everlywell, Fulgent Genetics, Zebra Medical Vision.
Read More
2-24-Viz-AI.png

Medicare NTAP no tap dance for some new technologies, pricing models

May 18, 2020
By Mari Serebrov
No Comments
Except for breakthrough devices and qualifying infectious disease drugs, the footwork for getting Medicare's new technology add-on payment (NTAP) can be more challenging than that needed to win FDA approval. It could be even tougher for products that use artificial intelligence (AI) or that follow a subscription model for pricing.
Read More

Regulatory front for May 18, 2020

May 18, 2020
No Comments
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for May 18, 2020

May 18, 2020
No Comments

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adamis, Akebia, Astrazeneca, Biosig, BMS, Carsgen, Cyclo, Cytodyn, Daiichi, Genentech, Lidds, Nantkwest, Sellas, Teva, Vistagen.


Read More

FDA approves Qinlock for fourth-line treatment of advanced GIST

May 18, 2020
No Comments

FDA grants accelerated approval to Rubraca for BRCA-mutated metastatic CRPC

May 18, 2020
No Comments

Opdivo + Yervoy approved in U.S. for first-line metastatic NSCLC with PD-L1 expression >= 1%

May 18, 2020
No Comments

FDA approves Pomalyst for AIDS-related and HIV-negative Kaposi sarcoma

May 18, 2020
No Comments
Previous 1 2 … 456 457 458 459 460 461 462 463 464 … 925 926 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 27, 2022.
  • Biogen, Eisai win FDA clearance for AD therapy Leqembi

    BioWorld
    As expected, the U.S. FDA gave its go-ahead to lecanemab, an amyloid-beta binder for mild cognitive impairment caused by Alzheimer’s disease (AD) and mild AD –...
  • Stem-cells2.png

    J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

    BioWorld
    After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing